Ielasi Alfonso, Cerrato Enrico, Geraci Salvatore, Campo Gianluca, Garro Nadia, Leoncini Massimo, Sganzerla Paolo, Granata Francesco, Ruggiero Rossella, Varbella Ferdinando, Caramanno Giuseppe, Grigis Giulietta, Tespili Maurizio
Cardiology Division, ASST Bergamo Est, Seriate, Italy,
Clinical and Interventional Cardiology Unit, Sant'Ambrogio Clinical Institute, Milan, Italy,
Cardiology. 2019;142(2):93-96. doi: 10.1159/000499536. Epub 2019 May 10.
To date, very little is known about the performance of a sirolimus-eluting bioresorbable magnesium scaffold (Mg-BRS) in patients with acute myocardial infarction (AMI). A multicenter cohort analysis was performed on 69 consecutive AMI subjects treated with Mg-BRS. Procedural success was obtained in all cases, and no in-hospital events were reported. At 9-month follow-up, no cardiac death, target-vessel myocardial infarction, ischemia-driven target lesion revascularization, or Mg-BRS thrombosis was reported. Although our analysis showed encouraging results, larger studies and longer-term follow-up are needed to better understand the potential benefits associated with the use of a Mg-BRS in AMI patients.
迄今为止，对于西罗莫司洗脱生物可吸收镁支架（Mg-BRS）在急性心肌梗死（AMI）患者中的性能了解甚少。对69例连续接受Mg-BRS治疗的AMI患者进行了多中心队列分析。所有病例均获得手术成功，且未报告院内事件。在9个月的随访中，未报告心脏死亡、靶血管心肌梗死、缺血驱动的靶病变血运重建或Mg-BRS血栓形成。尽管我们的分析显示了令人鼓舞的结果，但仍需要更大规模的研究和更长时间的随访，以更好地了解在AMI患者中使用Mg-BRS的潜在益处。
